<SEC-DOCUMENT>0000059478-22-000130.txt : 20220428
<SEC-HEADER>0000059478-22-000130.hdr.sgml : 20220428
<ACCEPTANCE-DATETIME>20220428070527
ACCESSION NUMBER:		0000059478-22-000130
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220428
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220428
DATE AS OF CHANGE:		20220428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		22862144

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20220428.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:eec62eb5-8f6a-427f-998f-5eef19ce8c55,g:2d920c5e-ea0d-4d7a-9a97-1e6e9a341ef1,d:bbf2c662cb4a4a1185ac6f9106131795--><html xmlns:lly="http://www.lilly.com/20220428" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20220428</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV80L2ZyYWc6NmZiZDU4MTQwZDM0NDgzODhhYmQ1NDc4ZmZkMjRiODIvdGFibGU6ZTZkMWI1YWIzM2Y2NDZmM2JiN2Y5ZjgxNDA4MGYyNzIvdGFibGVyYW5nZTplNmQxYjVhYjMzZjY0NmYzYmI3ZjlmODE0MDgwZjI3Ml8yLTEtMS0xLTEwMTE4MA_aef1d819-cbc0-478e-be07-e4a0c4993340">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV80L2ZyYWc6NmZiZDU4MTQwZDM0NDgzODhhYmQ1NDc4ZmZkMjRiODIvdGFibGU6ZTZkMWI1YWIzM2Y2NDZmM2JiN2Y5ZjgxNDA4MGYyNzIvdGFibGVyYW5nZTplNmQxYjVhYjMzZjY0NmYzYmI3ZjlmODE0MDgwZjI3Ml81LTEtMS0xLTEwMTE4MA_f05f4ebe-1af0-4279-942c-558526a32795">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20220428.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19730792f0584f169f27749a526c87ab_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5466896d0b5647358a407a0b1b926736_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibbf2c662cb4a4a1185ac6f9106131795_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg1_7fc5cee6-1911-4d8b-b607-ca75df5c0f65">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2.2pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xNTk_09e1ffac-31d3-4df3-9296-098acb5d53cf">April 28, 2022</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg2_47975bd3-6411-494e-829c-4bde1bb76bda">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6M2UxYWE0ODliZjUyNDdlNWFjMWViMzliZjAwNjIwN2QvdGFibGVyYW5nZTozZTFhYTQ4OWJmNTI0N2U1YWMxZWIzOWJmMDA2MjA3ZF8wLTAtMS0xLTEwMTE4MA_d87a654e-cfc9-4a84-9b46-9126e7eb89de">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6M2UxYWE0ODliZjUyNDdlNWFjMWViMzliZjAwNjIwN2QvdGFibGVyYW5nZTozZTFhYTQ4OWJmNTI0N2U1YWMxZWIzOWJmMDA2MjA3ZF8wLTItMS0xLTEwMTE4MA_76ef9383-94cb-42c5-a797-36d94176ab64">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6M2UxYWE0ODliZjUyNDdlNWFjMWViMzliZjAwNjIwN2QvdGFibGVyYW5nZTozZTFhYTQ4OWJmNTI0N2U1YWMxZWIzOWJmMDA2MjA3ZF8wLTQtMS0xLTEwMTE4MA_44ac007c-f626-4064-8ede-44fca7273eb0">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:21.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18wLTAtMS0xLTEwMTE4MA_82903ae1-19cb-47fc-8073-1021aca8d8b2">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18xLTAtMS0xLTEwMTE4MA_2839511f-8b96-4652-a0f0-dabbae28267a">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18xLTEtMS0xLTEwMTE4MA_72292ca5-f7b7-42b8-99ba-56481abc613d">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18xLTItMS0xLTEwMTE4MA_9f5feaea-88b8-49b4-abfc-027c356e5bd7">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg3_796845cc-5345-46ac-a0db-3379ad2fa255">317</ix:nonNumeric>) <ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg4_b0536360-3521-4605-a37b-7e35ce8156ce">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6MDJlZTcxM2MxOWI3NGUxNWJjMzVkMTJlYmZmYjVlODEvdGFibGVyYW5nZTowMmVlNzEzYzE5Yjc0ZTE1YmMzNWQxMmViZmZiNWU4MV8wLTAtMS0xLTEwMTE4MA_b12a03f0-f9c0-4a12-bc42-7f48b25c15f8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZDk3NGYxZmFiOGIwNDk4ZThlMzQxMWM1N2IyZTk2OTQvdGFibGVyYW5nZTpkOTc0ZjFmYWI4YjA0OThlOGUzNDExYzU3YjJlOTY5NF8wLTAtMS0xLTEwMTE4MA_e9dd455b-027c-4a3e-a0ec-32385748dbea">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6NjE1ZjdmODQ4Mjg3NDEwOTg1Nzg0NjBiOGFlODYyMzMvdGFibGVyYW5nZTo2MTVmN2Y4NDgyODc0MTA5ODU3ODQ2MGI4YWU4NjIzM18wLTAtMS0xLTEwMTE4MA_78d18bba-ac11-465b-ad2e-1351cf668d8c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6N2I2MjUyZTJhMmJkNDk4MWJkZDE2MmYyZjMzZjE3YmMvdGFibGVyYW5nZTo3YjYyNTJlMmEyYmQ0OTgxYmRkMTYyZjJmMzNmMTdiY18wLTAtMS0xLTEwMTE4MA_440c362a-4e37-4f23-a8d5-10f060d21dc8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xLTAtMS0xLTEwMTE4MA_639a5bf7-df5d-4fa0-a834-67e19c328495">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xLTItMS0xLTEwMTE4MA_04b0a6ae-5fcf-4ef4-8529-623de9af000a">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xLTQtMS0xLTEwMTE4MA_8f5d2578-76a0-438e-8695-bbf6d221a5d6">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8zLTAtMS0xLTEwMTE4MA_06d1dec8-188c-4d3f-ae56-337a03fd4e24">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8zLTItMS0xLTEwMTE4MA_ae63c2cb-5382-4511-b44a-ed6b17a85441">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8zLTQtMS0xLTEwMTE4MA_f61bbc6a-55b3-4dbe-8fd6-48f96ecbba12">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19730792f0584f169f27749a526c87ab_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl80LTAtMS0xLTEwMTE4MA_9bdc8006-a616-45b6-b0a7-72d1e8879385">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19730792f0584f169f27749a526c87ab_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl80LTItMS0xLTEwMTE4MA_de3526df-6e18-4a71-a0ca-d09c3ef86d4d">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19730792f0584f169f27749a526c87ab_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl80LTQtMS0xLTEwMTE4MA_bc8102f5-f31e-4886-a8ef-1cc3352cd5ea">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl81LTAtMS0xLTEwMTE4MA_15666054-32b4-4855-ac4f-57f2ed36f2d0">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl81LTItMS0xLTEwMTE4MA_5f8b87cb-7bd1-4159-b6d4-9045e7c52636">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl81LTQtMS0xLTEwMTE4MA_45068d22-e9b2-4abc-a702-77db77e96ec2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5466896d0b5647358a407a0b1b926736_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl82LTAtMS0xLTEwMTE4MA_9ae40b3e-aece-4814-9392-c622145bb4b7">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5466896d0b5647358a407a0b1b926736_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl82LTItMS0xLTEwMTE4MA_46721289-1761-4c6d-a4a5-144110ce66ee">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5466896d0b5647358a407a0b1b926736_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl82LTQtMS0xLTEwMTE4MA_9542b4a0-f754-437d-9dbc-c8771cac9afe">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl83LTAtMS0xLTEwMTE4MA_b1016815-a6c5-462f-8abe-a37fa4f3863a">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl83LTItMS0xLTEwMTE4MA_55d76632-f330-4269-98ce-d794c676d600">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl83LTQtMS0xLTEwMTE4MA_250e4fb8-6fdd-4ceb-82b8-26a56c7c5982">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl84LTAtMS0xLTEwMTE4MA_7b430078-4217-4d19-9eaf-0087c0bcd16c">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl84LTItMS0xLTEwMTE4MA_f0d16cde-bf3d-4414-a562-a9ea2aa0cdd6">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl84LTQtMS0xLTEwMTE4MA_78aafd3e-05aa-4097-9771-705bf9fdea4d">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl85LTAtMS0xLTEwMTE4MA_6a443ec6-3725-4b4b-8c1a-b89ecd8d4152">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl85LTItMS0xLTEwMTE4MA_995c5fd8-6efc-4b56-9b86-a45d900706df">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl85LTQtMS0xLTEwMTE4MA_8828b1d2-2d82-44be-b68e-0510711da505">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMC0wLTEtMS0xMDExODA_a4e363b1-44de-48b6-a417-769d2153e769">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMC0yLTEtMS0xMDExODA_95110874-8b27-4d9b-acb1-d0719eb65ab6">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMC00LTEtMS0xMDExODA_d789997b-e7b9-4bff-a3de-f08a78e47d66">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMS0wLTEtMS0xMDExODA_f9e72801-6a59-4505-bab6-b626a14bbd3f">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMS0yLTEtMS0xMDExODA_fc6c2af6-a964-4464-aa74-991ed1d46f7a">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMS00LTEtMS0xMDExODA_528cc991-fd6a-464b-a10e-b25f2473eeb8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMi0wLTEtMS0xMDExODA_5f322f15-228f-4fed-8e61-b1d8c37314ac">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMi0yLTEtMS0xMDExODA_497bae9d-8864-47cd-837a-388404c76b30">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMi00LTEtMS0xMDExODA_dda097f1-4fe7-4bae-b86b-f71cd7731f52">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg5_768b6664-6f6d-414d-a51d-6f435cf72842">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ibbf2c662cb4a4a1185ac6f9106131795_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated April 28, 2022, announcing the financial results of Eli Lilly and Company for the quarter ended March 31, 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q122lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q122lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q122lillysalesandearningsp.htm">April 28</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q122lillysalesandearningsp.htm">, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.666%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">April 28, 2022</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q122lillysalesandearningsp.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i147f97837ace4eeaa10bed2a64dd03dc_1"></div><div style="min-height:180pt;width:100%"><div style="text-align:right"><img alt="logoa31a.jpg" src="logoa31a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">April 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lilly Corporate Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indianapolis, Indiana  46285</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.A. </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+1.317.276.2000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:700;line-height:100%">www.lilly.com</font></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Release&#58; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Immediately</font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Refer to&#58;</font><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jordan Bishop&#59; jordan.bishop&#64;lilly.com&#59; (317) 473-5712 (Media)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Kevin Hern&#59; hern_kevin_r&#64;lilly.com&#59; (317) 277-1838 (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Outside of revenue from COVID-19 antibodies, which grew $660 million, revenue was driven by key growth products - consisting of Trulicity, Verzenio, Jardiance, Taltz, Olumiant, Emgality, Retevmo, Cyramza and Tyvyt - which contributed 13 percentage points of revenue growth and represented 61% of core revenue in Q1 2022.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">The company advanced its pipeline with a positive Phase 3 readout for tirzepatide for obesity or overweight, an announcement that the Phase 3 trial of Jardiance for people with chronic kidney disease will stop early due to clear positive efficacy, and a U.S. regulatory submission for mirikizumab for moderately-to-severely active ulcerative colitis.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Q1 2022 EPS increased 41% to $2.10 on a reported basis and increased 63% to $2.62 on a non-GAAP basis. Q1 2022 reported and non-GAAP EPS are both inclusive of $0.15 of acquired IPR&#38;D and development milestone charges. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">2022 EPS guidance updated to be in the range of $7.30 to $7.45 on a reported basis and $8.15 to $8.30 on a non-GAAP basis, both inclusive of $0.55 of acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">INDIANAPOLIS, April 28, 2022 - Eli Lilly and Company (NYSE&#58; LLY) today announced its financial results for the first quarter of 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#34;Lilly delivered another quarter of volume-driven revenue growth led by key products and anticipates 2022 to be an exciting year with several potential approvals and new pipeline events,&#34; said David A. Ricks, Lilly's chair and CEO. &#34;With the depth of our pipeline, and growth of our medicines in the market, we are well-positioned to help address health challenges in areas of significant unmet medical need, such as obesity, Alzheimer&#8217;s disease and cancer.&#34;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_4"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Today, the company is sharing new notable announcements&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in the 72-week Phase 3 SURMOUNT-1 study. Participants taking tirzepatide lost up to 52 lb. and 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reduction as a key secondary endpoint.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Lilly submitted mirikizumab to the U.S. Food and Drug Administration (FDA) </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">for the treatment of adults with moderately-to-severely active ulcerative colitis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA approved Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> to treat adults with heart failure regardless of left ventricular ejection fraction.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Bebtelovimab received Emergency Use Authorization (EUA) from the FDA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA issued a Complete Response Letter (CRL) for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">As anticipated, Lilly received a CRL from the FDA for the Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> atopic dermatitis indication as the company was not in alignment with the FDA on the indicated population.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Lebrikizumab combined with topical corticosteroids showed 70% of patients with moderate-to-severe atopic dermatitis experienced at least 75% reduction in disease severity at 16 weeks in the ADhere Phase 3 trial.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">More than 50% of patients with moderate-to-severe atopic dermatitis experienced at least 75% reduction in disease severity at 16 weeks with lebrikizumab in Lilly's pivotal Phase 3 atopic dermatitis ADvocate studies.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Nearly 40% of adults with alopecia areata taking Olumiant 4-mg saw at least 80% scalp hair coverage at 52 weeks in Lilly's pivotal Phase 3 studies.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Nearly two-thirds of patients responded to mirikizumab treatment at 12 weeks in Lilly's first-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">in-class ulcerative colitis Phase 3 LUCENT-1 study.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced that the Jardiance Phase 3 EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance following stabilization and prior to discharge compared with placebo in the Phase 3 EMPULSE trial.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Lilly supplied 600,000 doses of bebtelovimab to the U.S. government in an ongoing effort to provide COVID-19 treatment options.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced the launch of the Lilly Institute for Genetic Medicine and a $700 million investment to establish a new site in the Boston Seaport.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For additional information on these and other important public announcements, visit the news section of Lilly's website.</font></div><div><font><br></font></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_7"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Financial Results</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.006%"><tr><td style="width:1.0%"></td><td style="width:46.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.904%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Quarter</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$7,810.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$6,805.6</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,902.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,355.3</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">40%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.49</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">41%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2,372.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,465.5</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">62%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2.62</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.61</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">63%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">A discussion of the non-GAAP financial measures is included under &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#34; Beginning in 2022, presentations of non-GAAP financial measures will not include adjustments for upfront charges and development milestones related to acquired in-process research and development (IPR&#38;D). Non-GAAP financial measures for Q1 2021 have been adjusted to reflect this updated presentation.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">First-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2022, worldwide revenue was $7.81 billion, an increase of 15% compared with Q1 2021, primarily driven by a 20% increase in volume, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. Key growth products, consisting of Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Jardiance, Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Olumiant, Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, contributed 13 percentage points of revenue growth and represented 61% of total revenue for Q1 2022, excluding revenue from COVID-19 antibodies. The company recognized worldwide revenue of $1.47 billion from COVID-19 antibodies during Q1 2022 compared with $810.1 million in Q1 2021. Excluding revenue from COVID-19 antibodies and Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, which lost exclusivity in certain major markets, worldwide revenue increased 10% in Q1 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue in the U.S. increased 31%, to $5.17 billion, driven by a 32% increase in volume. The company recognized U.S. revenue from COVID-19 antibodies of $1.46 billion in Q1 2022 compared to $650.6 million in Q1 2021. Excluding revenue from COVID-19 antibodies and Alimta, revenue in the U.S. increased by 14% driven by key growth products.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. decreased 8%, to $2.64 billion, driven by a 7% decrease due to lower realized prices and a 5% decrease due to the unfavorable impact of foreign exchange rates, partially offset by a 4% increase in volume. The lower realized prices were primarily driven by the impact of the National Reimbursement Drug List (NRDL) formulary for certain products in China, particularly Tyvyt. The increase in volume outside the U.S. was largely driven by key growth products and sales of the company's rights to Cialis</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in Taiwan and Saudi Arabia, partially offset by decreased volume for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;4</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Alimta, Cymbalta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> resulting from the entry of generic competition, as well as decreased volume for COVID-19 antibodies. Excluding revenue from COVID-19 antibodies and Alimta, revenue outside the U.S. increased by 5%.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin increased 16%, to $5.74 billion, in Q1 2022 compared with Q1 2021. Gross margin as a percent of revenue was 73.5%, an increase of 1.1 percentage points compared with Q1 2021. </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The increase in gross margin percent was </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">primarily driven by an unfavorable effect in Q1 2021 of foreign exchange rates on international inventories sold, partially offset by increased sales of COVID-19 antibodies and, to a lesser extent, lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2022, research and development expenses decreased 4% to $1.61 billion, or 21% of revenue, largely driven by lower development expenses for COVID-19 antibodies, partially offset by higher development expenses for late-stage assets. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Marketing, selling and administrative expenses decreased 1% to $1.56 billion in Q1 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2022, the company recognized acquired IPR&#38;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">and development milestone charges of $165.6 million primarily related to a purchase of a Priority Review Voucher. In Q1 2021, the company recognized acquired IPR&#38;D and development milestone charges of $312.0 million primarily related to business development transactions with Rigel Pharmaceuticals, Inc. and Precision BioSciences, Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">There were no asset impairment, restructuring and other special charges recognized in Q1 2022. In Q1 2021, the company recognized asset impairment, restructuring and other special charges of $211.6 million, largely related to an intangible asset impairment resulting from the decision to sell the rights to Qbrexza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;5</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income in Q1 2022 was $2.40 billion, compared to</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> $1.16 billion i</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">n Q1 2021. Operating margin percent, defined as operating income as a percent of revenue, was 30.8%, which includes a negative impact of approximately 210 basis points attributed to acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) was expense of $350.7 million in Q1 2022, compared with income of $321.1 million in Q1 2021. The reduction in other income (expense) was primarily driven by net losses on investments in equity securities in Q1 2022 compared with net gains on investments in equity securities in Q1 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate was 7.3% in Q1 2022, compared with 8.2% in Q1 2021. The lower effective tax rate in Q1 2022 was largely driven by decreased tax expense related to net losses in 2022 and net gains in 2021 on investments in equity securities and decreased tax expense related to the implementation of the provision in the Tax Cuts and Jobs Act (the 2017 Tax Act) that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, partially offset by a lower net discrete tax benefit compared to the same period in 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q1 2022, net income and earnings per share (EPS) were $1.90&#160;billion and $2.10, respectively, compared with $1.36&#160;billion and $1.49 in Q1 2021. Q1 2022 EPS is </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of $0.15 of acquired IPR&#38;D and development milestone charges, compared with $0.27 in Q1 2021.</font></div><div><font><br></font></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_10"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">First-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q1 2022 gross margin increased 16%, to $5.94 billion compared with Q1 2021. Gross margin as a percent of revenue was 76.1%, an increase of 0.7 percentage points. </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The increase in gross margin percent was </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">primarily driven by an unfavorable effect in Q1 2021 of foreign exchange rates on international inventories sold, partially offset by increased sales of COVID-19 antibodies and, to a lesser extent, lower realized prices.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income on a non-GAAP basis increased $1.03 billion, or 66%, to $2.61 billion in Q1 2022 compared with Q1 2021. Operating margin percent was 33.4% on a non-GAAP basis, which includes a negative impact of approximately 210 basis points attributed to acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) on a non-GAAP basis was income of $37.7 million in Q1 2022, compared with income of $34.6 million in Q1 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate on a non-GAAP basis was 10.3% in Q1 2022, compared with 8.9% in Q1 2021. The higher effective tax rate for Q1 2022 reflects a lower net discrete tax benefit compared to the same period in 2021, partially offset by decreased tax expense related to the implementation of the 2017 Tax Act. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, in Q1 2022 net income and EPS were $2.37 billion and $2.62, respectively, compared with $1.47 billion and $1.61 in Q1 2021. Q1 2022 non-GAAP EPS is </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of $0.15 of acquired IPR&#38;D and development milestone charges, compared with $0.27 in Q1 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#34; table later in this press release.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Quarter</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.10</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">41%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net losses (gains) on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.25)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Partial reversal of COVID-19 antibodies inventory charge</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.07&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2.62</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">63%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding.</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestone charges</font></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.15&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.27&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(44)%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;8</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_25"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.358%"><tr><td style="width:1.0%"></td><td style="width:36.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.802%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.038%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt 0 3.25pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">First Quarter</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Trulicity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,741.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,452.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">20%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,469.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">810.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">81%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">618.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">617.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Taltz</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">488.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">403.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">21%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Verzenio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">469.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">269.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">74%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">419.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">312.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">34%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Alimta</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">343.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">559.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(38)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">273.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">321.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(15)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">255.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">193.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">32%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Cyramza</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">230.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">240.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">191.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">246.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(22)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Emgality</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">149.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">119.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Forteo</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">137.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">198.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(31)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tyvyt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">109.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(22)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Retevmo</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">41.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">16.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">7,810.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6,805.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab, and were made pursuant to EUAs or similar regulatory authorizations </font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Humalog includes Insulin Lispro</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Jardiance includes Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, and Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> XR</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Olumiant includes sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">baricitinib that were made pursuant to EUA or similar regulatory authorizations</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM &#8211; not meaningful</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;9</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Trulicity</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, worldwide Trulicity revenue was $1.74 billion, an increase of 20% compared with Q1 2021. U.S. revenue increased 18%, to $1.31 billion, driven by increased demand, partially offset by lower realized prices as well as wholesale and retail buying patterns. Revenue outside the U.S. was $427.4 million, an increase of 27%, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humalog</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, worldwide Humalog revenue remained flat compared with Q1 2021, at $618.2 million. Revenue in the U.S. increased 11%, to $368.9 million, primarily driven by higher realized prices due to changes to estimates for rebates and discounts in both periods and, to a lesser extent, increased demand. However, the company expects a decline for realized Humalog prices in the U.S. for the remainder of 2022, largely driven by patient assistance programs. Revenue outside the U.S. decreased 12%, to $249.3 million, driven by decreased volume, the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Taltz</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, worldwide Taltz revenue increased 21% compared with Q1 2021, to $488.1&#160;million. U.S. revenue increased 23%, to $307.2&#160;million, driven by increased demand and higher realized prices due to segment mix, partially offset by specialty pharmacy buying patterns. Revenue outside the U.S. increased 18%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to $180.8 million, driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Verzenio</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, worldwide Verzenio revenue increased 74% compared with Q1 2021, to $469.4 million. U.S. revenue was $301.5 million, an increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of 74%, primarily driven by increased demand. Revenue outside the U.S. was $167.9 million, an increase of 74%, largely driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;10</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Jardiance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's worldwide Jardiance revenue during Q1 2022 was $419.4 million, an increase of 34% compared with Q1 2021. U.S. revenue increased 52%, to $229.8 million, primarily driven by increased demand. Revenue outside the U.S. was $189.7 million, an increase of 18%, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Alimta</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, worldwide Alimta revenue decreased 38% compared with Q1 2021, to $343.9 million. U.S. revenue decreased 3%, to $254.3&#160;million, driven by decreased volume, partially offset by higher realized prices. Revenue outside the U.S. decreased 70%, to $89.7 million, largely driven by decreased volume due to entry of generic competition in certain markets and, to a lesser extent, lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company expects continued volume decline for Alimta as a result of the entry of generic competition due to the loss of patent exclusivity in Japan and major European markets. An alternative form of pemetrexed launched in the U.S. during Q1 2022 and the company expects multiple generics to launch in Q2 2022, causing a rapid and severe decline in revenue.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Olumiant</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, worldwide Olumiant revenue increased 32% compared with Q1 2021, to $255.6 million. U.S. revenue was $71.3 million, representing growth of $46.6&#160;million compared with Q1 2021. Revenue outside the U.S. was $184.3 million, an increase of 9%, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices. Increased volume </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;11</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">worldwide was partially driven by utilization of Olumiant for the treatment of hospitalized patients with COVID-19.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Emgality</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, Emgality generated worldwide revenue of $149.3 million, an increase of 25% compared with Q1 2021. U.S. revenue was $108.3 million, an increase of 7%, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. was $41.0 million, an increase of $23.0 million compared with Q1 2021, driven by increased demand. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Tyvyt</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q1 2022, the company's Tyvyt revenue in China was $85.5 million, a decrease of 22% compared with Q1 2021, driven by lower realized prices due to the impact of the NRDL formulary in China on Tyvyt, largely offset by increased demand. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Tyvyt is part of the company's alliance with Innovent. Lilly reports total sales of Tyvyt made by Lilly as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. Lilly also reports as revenue a portion of the gross margin for Tyvyt sales made by Innovent.&#160;</font></div><div><font><br></font></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_34"></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">2022 Financial Guidance </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company has updated certain elements of its 2022 financial guidance on both a reported and non-GAAP basis. EPS for 2022 is now expected to be in the range of $7.30 to $7.45 on a reported basis and $8.15 to $8.30 on a non-GAAP basis. The company's 2022 financial guidance reflects adjustments shown in the reconciliation table below. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;12</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.138%"><tr><td style="width:1.0%"></td><td style="width:60.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2022<br>Expectations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">% Change vs 2021</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$7.30 to $7.45</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">19% to 22%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.51</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net losses on investments in equity securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.34</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$8.15 to $8.30</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">10% to 12%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestone charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$.55</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Beginning in 2022, presentations of non-GAAP financial measures will not include adjustments for upfront charges and development milestones related to acquired IPR&#38;D. Non-GAAP financial measures for Q1 2021 have been adjusted to reflect this updated presentation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company now anticipates 2022 revenue to be between $28.8 billion and $29.3 billion. This $1.0 billion increase reflects additional COVID-19 antibodies revenue from the sale of 600,000 doses of bebtelovimab to the U.S. government in Q1 2022. An unfavorable impact from foreign exchange rates on revenue is offset by strength of the core business. The U.S. government has an option to purchase an additional 500,000 doses of bebtelovimab no later than July 31, 2022, but it is uncertain whether the option will be exercised, and any associated revenue is not included in guidance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin percent is now expected to be approximately 76% on a reported basis and 78% on a non-GAAP basis. The majority of this roughly 200 basis point reduction is due to the impact of Q1 bebtelovimab sales and, to a lesser extent, increased manufacturing costs due to inflation. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Research and development expenses were increased by $100 million and are now expected to be between $7.1 billion and $7.3 billion, driven by investment in late-stage pipeline assets. </font></div><div style="margin-top:5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;13</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company is now providing 2022 financial guidance for acquired IPR&#38;D and development milestone charges, which are expected to be approximately $520 million, reflecting Q1 2022 charges of $166 million, with the remainder primarily related to a charge associated with the buy-out of future obligations that were contingent upon the development, regulatory and commercial successes of the company's mutant-selective PI3K&#945; inhibitor. This financial guidance does not include any impact from potential or pending business development transactions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating margin percent has been reduced by 200 basis points and is now expected to be approximately 28% on a reported basis and approximately 30% on a non-GAAP basis primarily due to the negative impact attributable to acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) for 2022 is now expected to be expense in the range of $500 million to $400 million on a reported basis and is still expected to be expense in the range of $100 million to $0 on a non-GAAP basis. The company's updated reported guidance reflects the impact of net losses on investments in equity securities during Q1 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's financial results for Q1 2022 include the favorable impact related to the implementation of the provision of the 2017 Tax Act that requires capitalization and amortization of research and development expenses for tax purposes. The company's financial guidance assumes this provision of the 2017 Tax Act will be deferred or repealed by Congress effective for 2022. If this provision of the 2017 Tax Act is not deferred or repealed by Congress effective for 2022, the company expects the reported and non-GAAP tax rates to be approximately 10% to 11%.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;14</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The following table summarizes the company's updated 2022 financial guidance&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:44.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2022 Guidance</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Updated</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$27.8 to $28.3 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$28.8 to $29.3 billion</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 78%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 76%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 80%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 78%</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Marketing, Selling &#38; Administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.4 to $6.6 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.0 to $7.2 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.1 to $7.3 billion</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D &#38; Development Milestones</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. $520 million</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(100) million to $0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(500) to $(400) million</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(100) million to $0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 13% to 14%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.00 to $8.15</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.30 to $7.45</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.50 to $8.65</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$8.15 to $8.30</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin % (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 30%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 28%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin % (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 32%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 30%</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP guidance reflects adjustments presented in the earnings per share table above.</font></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;15</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_37"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the Q1 2022 financial results conference call through a link on Lilly's website at investor.lilly.com&#47;webcasts-and-presentations. The conference call will begin at 9 a.m. Eastern time today and will be available for replay via the website.</font></div><div><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Certain financial information for 2022 and 2021 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Beginning in 2022, presentations of non-GAAP financial measures will not include adjustments for upfront charges and development milestones related to acquired IPR&#38;D. Non-GAAP financial measures for Q1 2021 have been adjusted to reflect this updated presentation. The company's 2022 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.</font></div><div><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">About Lilly</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly unites caring with discovery to create medicines that make life better for people around the world. We&#8217;ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47</font><font style="color:#4472c4;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world&#8217;s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer&#8217;s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we&#8217;re </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;16</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">motivated by one thing&#58; making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly.com and Lilly.com&#47;newsroom.</font><font style="color:#1f497d;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">F-LLY</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#34;estimate&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;expect&#34;, &#34;believe&#34;, &#34;target&#34;, &#34;anticipate&#34; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including the impact of the evolving COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat and the global response thereto&#59; uncertainties related to the company's efforts to develop, manufacture, and distribute potential treatments for COVID-19&#59; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals&#59; the impact of acquisitions and business development transactions and related integration costs&#59; the expiration of intellectual property protection for certain of the company's products and competition from generic and&#47;or biosimilar products&#59; the company's ability to protect and enforce patents and other intellectual property&#59; changes in patent law or regulations related to data package exclusivity&#59; competitive developments affecting current products and the company's pipeline&#59; market uptake of recently launched products&#59; information technology system inadequacies, breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's IT systems, networks, and facilities, or those of third parties with whom the company shares its data&#59; unexpected safety or efficacy concerns associated with the company's products&#59; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured&#59; issues with product supply and regulatory approvals stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions related to our facilities&#59; reliance on third-party relationships and outsourcing arrangements&#59; regulatory changes or other developments&#59; regulatory actions regarding currently marketed products&#59; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals&#59; devaluations in foreign currency exchange rates or changes in interest rates, and inflation&#59; changes in tax law, tax rates, or events that differ from the company's assumptions related to tax positions&#59; asset impairments and restructuring charges&#59; the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions&#59; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC)&#59; and regulatory compliance problems or government investigations. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pemetrexed disodium, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin glargine injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cialis</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (tadalafil, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cymbalta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (duloxetine, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (ramucirumab, Lilly)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;17</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (galcanezumab-gnlm, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (teriparatide of recombinant DNA origin injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;linagliptin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (human insulin of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(empagliflozin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (baricitinib, Lilly)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Qbrexza</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium cloth, Dermira)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(selpercatinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;metformin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(ixekizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> XR (empagliflozin&#47;linagliptin&#47;metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(dulaglutide, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (sintilimab injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (abemaciclib, Lilly)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Third party trademarks used herein are trademarks of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;18</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.736%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,805.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,072.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,878.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,610.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,672.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling and administrative</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,557.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,576.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(1)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestones</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">165.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">312.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(47)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">211.6&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(100)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,404.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,155.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(77.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(82.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(272.8)</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">403.4&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(350.7)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">321.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,053.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,476.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">39%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">150.7&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">24%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,902.9&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,355.3&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">40%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.49&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">41%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousands) - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">906,350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">912,419&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;19</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i147f97837ace4eeaa10bed2a64dd03dc_43"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:21.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended <br>March 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31, 2021</font></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2,072.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(204.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,867.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,878.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(207.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,671.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">211.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(350.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">388.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">321.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(286.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">150.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">123.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">273.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">121.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">143.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,902.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">469.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2,372.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,355.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">110.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,465.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">2.10</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.&#160;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. Beginning in 2022, presentations of non-GAAP financial measures will not include adjustments for upfront charges and development milestones related to acquired IPR&#38;D. Non-GAAP financial measures for Q1 2021 have been adjusted to reflect this updated presentation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;20</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the three months ended March&#160;31, 2022, include the following&#58; </font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.050%"><tr><td style="width:1.0%"></td><td style="width:37.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(204.6)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(204.6)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">388.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">388.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">42.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">80.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">123.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">307.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">469.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.52</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the three months ended March&#160;31, 2021, include the following&#58;</font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.559%"><tr><td style="width:1.0%"></td><td style="width:34.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.291%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.291%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(125.7)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(81.5)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(207.2)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(286.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(286.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(55.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">51.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">22.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(230.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">241.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">110.2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.12</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily an intangible asset impairment resulting from the decision to sell the rights to Qbrexza, charges resulting from excess inventory due in part to the discontinuation of bamlanivimab for use on its own, as well as acquisition and integration costs recognized as part of the closing of the acquisition of Prevail Therapeutics Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;21</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20220428.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:eec62eb5-8f6a-427f-998f-5eef19ce8c55,g:2d920c5e-ea0d-4d7a-9a97-1e6e9a341ef1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20220428" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20220428">
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20220428_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20220428_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20220428_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lly-20220428_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:eec62eb5-8f6a-427f-998f-5eef19ce8c55,g:2d920c5e-ea0d-4d7a-9a97-1e6e9a341ef1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20220428.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i1ac04cb5d99e47ac8d771d46c59f58cd_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5bca8e73-c89b-4a19-8a5a-1cf1a7beb24d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_DocumentType_5bca8e73-c89b-4a19-8a5a-1cf1a7beb24d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_caa9613d-fef0-4bd8-a693-ea5fad37b1db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_DocumentPeriodEndDate_caa9613d-fef0-4bd8-a693-ea5fad37b1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bf3f6848-238d-40cd-b750-94cbef2b0004" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bf3f6848-238d-40cd-b750-94cbef2b0004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ecfac3a9-b288-46ad-b20a-8490836138eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityFileNumber_ecfac3a9-b288-46ad-b20a-8490836138eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9b56aaff-ab29-43e9-b0f5-26cf7b4bc270" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityTaxIdentificationNumber_9b56aaff-ab29-43e9-b0f5-26cf7b4bc270" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1d782401-d8d4-4068-9c43-7468c28e312c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressAddressLine1_1d782401-d8d4-4068-9c43-7468c28e312c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bdd8320b-2ead-4c60-a125-45215814aaa0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressCityOrTown_bdd8320b-2ead-4c60-a125-45215814aaa0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_49ea85bc-647e-4e3b-ba10-d1012e76173a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressStateOrProvince_49ea85bc-647e-4e3b-ba10-d1012e76173a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f77ba030-6d04-4aaf-baae-b2b9b68d4153" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressPostalZipCode_f77ba030-6d04-4aaf-baae-b2b9b68d4153" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a80ad4d3-119d-4c2a-b721-8569d6bcc885" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_CityAreaCode_a80ad4d3-119d-4c2a-b721-8569d6bcc885" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d4dcdf46-0151-4d44-99f9-618e19572d2d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_LocalPhoneNumber_d4dcdf46-0151-4d44-99f9-618e19572d2d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_97e739a9-23f4-4f1c-bc17-90aca41f180d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_WrittenCommunications_97e739a9-23f4-4f1c-bc17-90aca41f180d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_f17e9a6e-5fd6-4e73-aae7-143ef4ff00b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_SolicitingMaterial_f17e9a6e-5fd6-4e73-aae7-143ef4ff00b2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d49e93fb-937e-46a3-b102-eccca4076a2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_PreCommencementTenderOffer_d49e93fb-937e-46a3-b102-eccca4076a2f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_441e2b80-f9b1-4554-9387-d78c576ba537" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_441e2b80-f9b1-4554-9387-d78c576ba537" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_13f6deed-3235-4b79-923f-d5d9ab39a520" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityEmergingGrowthCompany_13f6deed-3235-4b79-923f-d5d9ab39a520" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_86e84a7b-0842-41ae-b06a-4c8ca5eadd08" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_Security12bTitle_86e84a7b-0842-41ae-b06a-4c8ca5eadd08" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3a6133cf-9cf9-4fe9-a6bd-07d9100e104f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_TradingSymbol_3a6133cf-9cf9-4fe9-a6bd-07d9100e104f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_358e529e-d07a-4fed-8109-8c42fe1df835" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_SecurityExchangeName_358e529e-d07a-4fed-8109-8c42fe1df835" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_03f00466-d193-46ab-9629-8b233a6b932c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityRegistrantName_03f00466-d193-46ab-9629-8b233a6b932c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6f6340de-a924-4e44-806b-bfc5245033a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityCentralIndexKey_6f6340de-a924-4e44-806b-bfc5245033a1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0be6f323-ae3c-477a-b9b5-17b9e506efd0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_AmendmentFlag_0be6f323-ae3c-477a-b9b5-17b9e506efd0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8ca931aa-a075-4a0f-936a-307221381325" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_DocumentInformationTable_8ca931aa-a075-4a0f-936a-307221381325" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_28bf9c37-94b9-4987-b289-1a78870a5d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_8ca931aa-a075-4a0f-936a-307221381325" xlink:to="loc_us-gaap_StatementClassOfStockAxis_28bf9c37-94b9-4987-b289-1a78870a5d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_28bf9c37-94b9-4987-b289-1a78870a5d88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_28bf9c37-94b9-4987-b289-1a78870a5d88" xlink:to="loc_us-gaap_ClassOfStockDomain_28bf9c37-94b9-4987-b289-1a78870a5d88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_28bf9c37-94b9-4987-b289-1a78870a5d88" xlink:to="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_31451a94-6953-40c8-a05d-19915a4f066a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_us-gaap_CommonClassAMember_31451a94-6953-40c8-a05d-19915a4f066a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_28dc744d-5394-478d-892c-1d20e4ba0014" xlink:href="lly-20220428.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A718NotesDueJune12025Member_28dc744d-5394-478d-892c-1d20e4ba0014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_33324542-2911-4d4a-ad48-9d71f3414d5b" xlink:href="lly-20220428.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1.625NotesDueJune22026Member_33324542-2911-4d4a-ad48-9d71f3414d5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_c4a60dce-d7c1-466f-a643-a66d811e136e" xlink:href="lly-20220428.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A2.125NotesDueJune32030Member_c4a60dce-d7c1-466f-a643-a66d811e136e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_1473b754-706b-496e-b1eb-beca7432a334" xlink:href="lly-20220428.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A625Notesdue2031Member_1473b754-706b-496e-b1eb-beca7432a334" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_25302e29-966c-4011-9f33-fe3459427e2b" xlink:href="lly-20220428.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_25302e29-966c-4011-9f33-fe3459427e2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_e118efa8-0849-4429-b3e0-70ce2463ce45" xlink:href="lly-20220428.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1.700Notesdue2049Member_e118efa8-0849-4429-b3e0-70ce2463ce45" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_4e0573d5-d264-4d13-9331-d25b9d7c8bdb" xlink:href="lly-20220428.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A500NotesDue2033Member_4e0573d5-d264-4d13-9331-d25b9d7c8bdb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_4a5059ff-92eb-4e1f-b565-5a7fbaae17b8" xlink:href="lly-20220428.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1625NotesDue2043Member_4a5059ff-92eb-4e1f-b565-5a7fbaae17b8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_2b7e5a12-efed-4d3b-baa3-b9cd35ec9386" xlink:href="lly-20220428.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1125NotesDue2051Member_2b7e5a12-efed-4d3b-baa3-b9cd35ec9386" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_867eef12-9605-4c02-9deb-3f9138c013f7" xlink:href="lly-20220428.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1375NotesDue2061Member_867eef12-9605-4c02-9deb-3f9138c013f7" xlink:type="arc" order="10"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lly-20220428_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:eec62eb5-8f6a-427f-998f-5eef19ce8c55,g:2d920c5e-ea0d-4d7a-9a97-1e6e9a341ef1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_97783135-2fc5-49f6-9f3b-3d0ddb3d4f1e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_48346054-55d0-4bcf-a31b-132b5ecb9b65_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_24114da9-c57b-4b69-a9df-a16bef0afa5e_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20220428.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_978a8f08-c9b8-4df7-9933-48be9d77c9d7_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20220428.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_44013ab2-56e8-4973-af0f-36d76445d860_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20220428.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_4e46df2e-c254-42df-83bb-1387701b4a27_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20220428.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_6547219a-0dbf-46c6-babb-c0f41679e566_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20220428.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0a9fcb25-3fc2-46df-956b-cec52a12c4d3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_16d79ae4-2a00-44e3-b50d-f97f4dc2f7e9_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20220428.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_39a889ae-4571-4913-af85-2a48a866919c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_085219ba-6db9-4245-8d47-834af435bcca_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20220428.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_71b0109c-774a-455b-9a08-3afd5b70b11e_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20220428.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_e48ca0d5-ecbf-4b0b-8dcd-bea7030b509f_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_253259ef-c326-4230-a6d4-e8fdcec4ba4a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cfb0a90f-83c3-4692-8bec-bb52328d6b23_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8791f7e1-102d-420d-8aec-20ef47e8ec78_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_6700965e-a418-4f8f-87dc-b84b0efc15c1_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20220428.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_062f63ad-89f7-47f7-9b62-9db1a68d9af4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_272b15e4-8c63-4925-ba3e-443a9d0d9629_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9a6b6dcf-0967-4e50-b2cc-77e429f24113_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3ba300a5-b7e2-4b70-986b-3d935a2bffc6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_09e207d8-0393-4bed-aebc-7bb6d4606fdf_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_524a48af-bb68-4ee9-abee-9cef7e6a93d5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3b46f77d-8ca0-412b-8a6e-dc9ed8496b70_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7c174595-f688-4b44-a7ff-a84f456ae926_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_db9a8477-6f30-4097-b4ce-85717dba980e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_18b44446-703f-4c01-8ef4-9a1da1b2b655_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_ab9ee2dd-55b1-4240-8028-b272194c7d5f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_6fd39ca1-87ec-4c20-869a-0b73a4af0a9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bd51ad41-4ba1-4159-b933-87d637c6345c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_99d8a6ad-5b39-432c-9d47-643932c20db4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_12b8416e-2e80-461a-a628-1af277780627_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_7d6e0662-e156-4322-b5a3-9daa39819b7a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8331150a-bfec-43b7-881b-4375bc4b3f91_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_625d4569-d496-4f6f-9e8d-06262d896c0e_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20220428.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_092ad6ce-ea91-4e5a-98db-50a953d444f3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bac7f8f8-7a8c-46df-86da-df3a1e3c949b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_38e35a30-fb1a-4ed2-8aca-3f358db77333_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lly-20220428_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:eec62eb5-8f6a-427f-998f-5eef19ce8c55,g:2d920c5e-ea0d-4d7a-9a97-1e6e9a341ef1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20220428.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_50f57518-204f-471a-8cf6-711c51bb6d62" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8ca931aa-a075-4a0f-936a-307221381325" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_50f57518-204f-471a-8cf6-711c51bb6d62" xlink:to="loc_dei_DocumentInformationTable_8ca931aa-a075-4a0f-936a-307221381325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_28bf9c37-94b9-4987-b289-1a78870a5d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8ca931aa-a075-4a0f-936a-307221381325" xlink:to="loc_us-gaap_StatementClassOfStockAxis_28bf9c37-94b9-4987-b289-1a78870a5d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_28bf9c37-94b9-4987-b289-1a78870a5d88" xlink:to="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_31451a94-6953-40c8-a05d-19915a4f066a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_us-gaap_CommonClassAMember_31451a94-6953-40c8-a05d-19915a4f066a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_28dc744d-5394-478d-892c-1d20e4ba0014" xlink:href="lly-20220428.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A718NotesDueJune12025Member_28dc744d-5394-478d-892c-1d20e4ba0014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_33324542-2911-4d4a-ad48-9d71f3414d5b" xlink:href="lly-20220428.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1.625NotesDueJune22026Member_33324542-2911-4d4a-ad48-9d71f3414d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_c4a60dce-d7c1-466f-a643-a66d811e136e" xlink:href="lly-20220428.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A2.125NotesDueJune32030Member_c4a60dce-d7c1-466f-a643-a66d811e136e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_1473b754-706b-496e-b1eb-beca7432a334" xlink:href="lly-20220428.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A625Notesdue2031Member_1473b754-706b-496e-b1eb-beca7432a334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_25302e29-966c-4011-9f33-fe3459427e2b" xlink:href="lly-20220428.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_25302e29-966c-4011-9f33-fe3459427e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_e118efa8-0849-4429-b3e0-70ce2463ce45" xlink:href="lly-20220428.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1.700Notesdue2049Member_e118efa8-0849-4429-b3e0-70ce2463ce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_4e0573d5-d264-4d13-9331-d25b9d7c8bdb" xlink:href="lly-20220428.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A500NotesDue2033Member_4e0573d5-d264-4d13-9331-d25b9d7c8bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_4a5059ff-92eb-4e1f-b565-5a7fbaae17b8" xlink:href="lly-20220428.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1625NotesDue2043Member_4a5059ff-92eb-4e1f-b565-5a7fbaae17b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_2b7e5a12-efed-4d3b-baa3-b9cd35ec9386" xlink:href="lly-20220428.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1125NotesDue2051Member_2b7e5a12-efed-4d3b-baa3-b9cd35ec9386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_867eef12-9605-4c02-9deb-3f9138c013f7" xlink:href="lly-20220428.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e454501f-197e-4061-addc-1d56879753bc" xlink:to="loc_lly_A1375NotesDue2061Member_867eef12-9605-4c02-9deb-3f9138c013f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8ca931aa-a075-4a0f-936a-307221381325" xlink:to="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5bca8e73-c89b-4a19-8a5a-1cf1a7beb24d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_DocumentType_5bca8e73-c89b-4a19-8a5a-1cf1a7beb24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_caa9613d-fef0-4bd8-a693-ea5fad37b1db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_DocumentPeriodEndDate_caa9613d-fef0-4bd8-a693-ea5fad37b1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bf3f6848-238d-40cd-b750-94cbef2b0004" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bf3f6848-238d-40cd-b750-94cbef2b0004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ecfac3a9-b288-46ad-b20a-8490836138eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityFileNumber_ecfac3a9-b288-46ad-b20a-8490836138eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9b56aaff-ab29-43e9-b0f5-26cf7b4bc270" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityTaxIdentificationNumber_9b56aaff-ab29-43e9-b0f5-26cf7b4bc270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1d782401-d8d4-4068-9c43-7468c28e312c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressAddressLine1_1d782401-d8d4-4068-9c43-7468c28e312c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bdd8320b-2ead-4c60-a125-45215814aaa0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressCityOrTown_bdd8320b-2ead-4c60-a125-45215814aaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_49ea85bc-647e-4e3b-ba10-d1012e76173a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressStateOrProvince_49ea85bc-647e-4e3b-ba10-d1012e76173a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f77ba030-6d04-4aaf-baae-b2b9b68d4153" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityAddressPostalZipCode_f77ba030-6d04-4aaf-baae-b2b9b68d4153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a80ad4d3-119d-4c2a-b721-8569d6bcc885" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_CityAreaCode_a80ad4d3-119d-4c2a-b721-8569d6bcc885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d4dcdf46-0151-4d44-99f9-618e19572d2d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_LocalPhoneNumber_d4dcdf46-0151-4d44-99f9-618e19572d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_97e739a9-23f4-4f1c-bc17-90aca41f180d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_WrittenCommunications_97e739a9-23f4-4f1c-bc17-90aca41f180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_f17e9a6e-5fd6-4e73-aae7-143ef4ff00b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_SolicitingMaterial_f17e9a6e-5fd6-4e73-aae7-143ef4ff00b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d49e93fb-937e-46a3-b102-eccca4076a2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_PreCommencementTenderOffer_d49e93fb-937e-46a3-b102-eccca4076a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_441e2b80-f9b1-4554-9387-d78c576ba537" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_441e2b80-f9b1-4554-9387-d78c576ba537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_13f6deed-3235-4b79-923f-d5d9ab39a520" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityEmergingGrowthCompany_13f6deed-3235-4b79-923f-d5d9ab39a520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_86e84a7b-0842-41ae-b06a-4c8ca5eadd08" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_Security12bTitle_86e84a7b-0842-41ae-b06a-4c8ca5eadd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3a6133cf-9cf9-4fe9-a6bd-07d9100e104f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_TradingSymbol_3a6133cf-9cf9-4fe9-a6bd-07d9100e104f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_358e529e-d07a-4fed-8109-8c42fe1df835" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_SecurityExchangeName_358e529e-d07a-4fed-8109-8c42fe1df835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_03f00466-d193-46ab-9629-8b233a6b932c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityRegistrantName_03f00466-d193-46ab-9629-8b233a6b932c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6f6340de-a924-4e44-806b-bfc5245033a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_EntityCentralIndexKey_6f6340de-a924-4e44-806b-bfc5245033a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0be6f323-ae3c-477a-b9b5-17b9e506efd0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eaf1196c-5c0c-42dc-9d88-b5c9cef9269c" xlink:to="loc_dei_AmendmentFlag_0be6f323-ae3c-477a-b9b5-17b9e506efd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logoa31a.jpg
<TEXT>
begin 644 logoa31a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
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M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
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M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
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MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140237571139848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 28,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625%&#160;Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>lly-20220428_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20220428"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20220428.xsd" xlink:type="simple"/>
    <context id="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i19730792f0584f169f27749a526c87ab_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i5466896d0b5647358a407a0b1b926736_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV80L2ZyYWc6NmZiZDU4MTQwZDM0NDgzODhhYmQ1NDc4ZmZkMjRiODIvdGFibGU6ZTZkMWI1YWIzM2Y2NDZmM2JiN2Y5ZjgxNDA4MGYyNzIvdGFibGVyYW5nZTplNmQxYjVhYjMzZjY0NmYzYmI3ZjlmODE0MDgwZjI3Ml8yLTEtMS0xLTEwMTE4MA_aef1d819-cbc0-478e-be07-e4a0c4993340">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV80L2ZyYWc6NmZiZDU4MTQwZDM0NDgzODhhYmQ1NDc4ZmZkMjRiODIvdGFibGU6ZTZkMWI1YWIzM2Y2NDZmM2JiN2Y5ZjgxNDA4MGYyNzIvdGFibGVyYW5nZTplNmQxYjVhYjMzZjY0NmYzYmI3ZjlmODE0MDgwZjI3Ml81LTEtMS0xLTEwMTE4MA_f05f4ebe-1af0-4279-942c-558526a32795">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg1_7fc5cee6-1911-4d8b-b607-ca75df5c0f65">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xNTk_09e1ffac-31d3-4df3-9296-098acb5d53cf">2022-04-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg2_47975bd3-6411-494e-829c-4bde1bb76bda">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6M2UxYWE0ODliZjUyNDdlNWFjMWViMzliZjAwNjIwN2QvdGFibGVyYW5nZTozZTFhYTQ4OWJmNTI0N2U1YWMxZWIzOWJmMDA2MjA3ZF8wLTAtMS0xLTEwMTE4MA_d87a654e-cfc9-4a84-9b46-9126e7eb89de">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6M2UxYWE0ODliZjUyNDdlNWFjMWViMzliZjAwNjIwN2QvdGFibGVyYW5nZTozZTFhYTQ4OWJmNTI0N2U1YWMxZWIzOWJmMDA2MjA3ZF8wLTItMS0xLTEwMTE4MA_76ef9383-94cb-42c5-a797-36d94176ab64">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6M2UxYWE0ODliZjUyNDdlNWFjMWViMzliZjAwNjIwN2QvdGFibGVyYW5nZTozZTFhYTQ4OWJmNTI0N2U1YWMxZWIzOWJmMDA2MjA3ZF8wLTQtMS0xLTEwMTE4MA_44ac007c-f626-4064-8ede-44fca7273eb0">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18wLTAtMS0xLTEwMTE4MA_82903ae1-19cb-47fc-8073-1021aca8d8b2">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18xLTAtMS0xLTEwMTE4MA_2839511f-8b96-4652-a0f0-dabbae28267a">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18xLTEtMS0xLTEwMTE4MA_72292ca5-f7b7-42b8-99ba-56481abc613d">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6OWI2MDQxNTM3Zjg4NGIzNGJkMTQ3MWYzYmE4ZjgxMGMvdGFibGVyYW5nZTo5YjYwNDE1MzdmODg0YjM0YmQxNDcxZjNiYThmODEwY18xLTItMS0xLTEwMTE4MA_9f5feaea-88b8-49b4-abfc-027c356e5bd7">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg3_796845cc-5345-46ac-a0db-3379ad2fa255">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg4_b0536360-3521-4605-a37b-7e35ce8156ce">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6MDJlZTcxM2MxOWI3NGUxNWJjMzVkMTJlYmZmYjVlODEvdGFibGVyYW5nZTowMmVlNzEzYzE5Yjc0ZTE1YmMzNWQxMmViZmZiNWU4MV8wLTAtMS0xLTEwMTE4MA_b12a03f0-f9c0-4a12-bc42-7f48b25c15f8">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZDk3NGYxZmFiOGIwNDk4ZThlMzQxMWM1N2IyZTk2OTQvdGFibGVyYW5nZTpkOTc0ZjFmYWI4YjA0OThlOGUzNDExYzU3YjJlOTY5NF8wLTAtMS0xLTEwMTE4MA_e9dd455b-027c-4a3e-a0ec-32385748dbea">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6NjE1ZjdmODQ4Mjg3NDEwOTg1Nzg0NjBiOGFlODYyMzMvdGFibGVyYW5nZTo2MTVmN2Y4NDgyODc0MTA5ODU3ODQ2MGI4YWU4NjIzM18wLTAtMS0xLTEwMTE4MA_78d18bba-ac11-465b-ad2e-1351cf668d8c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6N2I2MjUyZTJhMmJkNDk4MWJkZDE2MmYyZjMzZjE3YmMvdGFibGVyYW5nZTo3YjYyNTJlMmEyYmQ0OTgxYmRkMTYyZjJmMzNmMTdiY18wLTAtMS0xLTEwMTE4MA_440c362a-4e37-4f23-a8d5-10f060d21dc8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xLTAtMS0xLTEwMTE4MA_639a5bf7-df5d-4fa0-a834-67e19c328495">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xLTItMS0xLTEwMTE4MA_04b0a6ae-5fcf-4ef4-8529-623de9af000a">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0c4093086fb2418b85592e535348e4a2_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xLTQtMS0xLTEwMTE4MA_8f5d2578-76a0-438e-8695-bbf6d221a5d6">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8zLTAtMS0xLTEwMTE4MA_06d1dec8-188c-4d3f-ae56-337a03fd4e24">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8zLTItMS0xLTEwMTE4MA_ae63c2cb-5382-4511-b44a-ed6b17a85441">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icd2070ee453941f0a4477c661e09fabd_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8zLTQtMS0xLTEwMTE4MA_f61bbc6a-55b3-4dbe-8fd6-48f96ecbba12">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i19730792f0584f169f27749a526c87ab_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl80LTAtMS0xLTEwMTE4MA_9bdc8006-a616-45b6-b0a7-72d1e8879385">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i19730792f0584f169f27749a526c87ab_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl80LTItMS0xLTEwMTE4MA_de3526df-6e18-4a71-a0ca-d09c3ef86d4d">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i19730792f0584f169f27749a526c87ab_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl80LTQtMS0xLTEwMTE4MA_bc8102f5-f31e-4886-a8ef-1cc3352cd5ea">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl81LTAtMS0xLTEwMTE4MA_15666054-32b4-4855-ac4f-57f2ed36f2d0">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl81LTItMS0xLTEwMTE4MA_5f8b87cb-7bd1-4159-b6d4-9045e7c52636">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iadefa48af9fa440fa70d984f2f12e095_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl81LTQtMS0xLTEwMTE4MA_45068d22-e9b2-4abc-a702-77db77e96ec2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i5466896d0b5647358a407a0b1b926736_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl82LTAtMS0xLTEwMTE4MA_9ae40b3e-aece-4814-9392-c622145bb4b7">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5466896d0b5647358a407a0b1b926736_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl82LTItMS0xLTEwMTE4MA_46721289-1761-4c6d-a4a5-144110ce66ee">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5466896d0b5647358a407a0b1b926736_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl82LTQtMS0xLTEwMTE4MA_9542b4a0-f754-437d-9dbc-c8771cac9afe">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl83LTAtMS0xLTEwMTE4MA_b1016815-a6c5-462f-8abe-a37fa4f3863a">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl83LTItMS0xLTEwMTE4MA_55d76632-f330-4269-98ce-d794c676d600">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if54ea75a0fba4ca398cd5a2fa2816803_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl83LTQtMS0xLTEwMTE4MA_250e4fb8-6fdd-4ceb-82b8-26a56c7c5982">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl84LTAtMS0xLTEwMTE4MA_7b430078-4217-4d19-9eaf-0087c0bcd16c">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl84LTItMS0xLTEwMTE4MA_f0d16cde-bf3d-4414-a562-a9ea2aa0cdd6">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib5b31f7a7d2546b2999aec253c1fbe8d_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl84LTQtMS0xLTEwMTE4MA_78aafd3e-05aa-4097-9771-705bf9fdea4d">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl85LTAtMS0xLTEwMTE4MA_6a443ec6-3725-4b4b-8c1a-b89ecd8d4152">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl85LTItMS0xLTEwMTE4MA_995c5fd8-6efc-4b56-9b86-a45d900706df">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id84c6f14322946e5ab93f5908d507f61_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl85LTQtMS0xLTEwMTE4MA_8828b1d2-2d82-44be-b68e-0510711da505">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMC0wLTEtMS0xMDExODA_a4e363b1-44de-48b6-a417-769d2153e769">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMC0yLTEtMS0xMDExODA_95110874-8b27-4d9b-acb1-d0719eb65ab6">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i30f9c0cb0dd54374882d5a6a7df732fa_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMC00LTEtMS0xMDExODA_d789997b-e7b9-4bff-a3de-f08a78e47d66">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMS0wLTEtMS0xMDExODA_f9e72801-6a59-4505-bab6-b626a14bbd3f">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMS0yLTEtMS0xMDExODA_fc6c2af6-a964-4464-aa74-991ed1d46f7a">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6fb95abaeb4a469d93e79e27e13a070a_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMS00LTEtMS0xMDExODA_528cc991-fd6a-464b-a10e-b25f2473eeb8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMi0wLTEtMS0xMDExODA_5f322f15-228f-4fed-8e61-b1d8c37314ac">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMi0yLTEtMS0xMDExODA_497bae9d-8864-47cd-837a-388404c76b30">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0607b01ffde7409ca05926a2e66b7ecb_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGFibGU6ZmViN2JlYTgyYTgzNDU0ZWI3MGI0ODYyNzc3NTllNGIvdGFibGVyYW5nZTpmZWI3YmVhODJhODM0NTRlYjcwYjQ4NjI3Nzc1OWU0Yl8xMi00LTEtMS0xMDExODA_dda097f1-4fe7-4bae-b86b-f71cd7731f52">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiZjJjNjYyY2I0YTRhMTE4NWFjNmY5MTA2MTMxNzk1L3NlYzpiYmYyYzY2MmNiNGE0YTExODVhYzZmOTEwNjEzMTc5NV8xL2ZyYWc6YWM4NDE4YjY1NTc2NDg5OWFjMTg3MTBlNmM4YjQwM2IvdGV4dHJlZ2lvbjphYzg0MThiNjU1NzY0ODk5YWMxODcxMGU2YzhiNDAzYl8xMTg5_768b6664-6f6d-414d-a51d-6f435cf72842">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M=Z*]N;I)C0U].>$/Y .OK9M%RC%_P9D?=3%G 'N*H[FGTY94B7N?L4FM'US
M-HYT8\EN8;O.OU[IC)2(OY%7A2 S)LD]R^;\-:8/R*;>T>X)*&"8XO2\395>
M3(HQ<>FKN]=DQ..Y!G/]2.-*_[,>0&>*<_56LL1,Y=%C?B=JP6P1T#,%,P)8
MICA&GVI$KA[B*2LF?.L$M@C=?!U=88X QQ3G9D3<3O=G<B,4+TDRY^:V%%O
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MC'\6I;TKL?'[U*'\LPCH /IG/<P+ #!H"H 6(5L" 8 !#D"G';RLN^=ARD#
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" "I.)Q4EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ J3B<5 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "I
M.)Q4\BI.N.\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "I.)Q4F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *DXG%1P_6%X
M; 8  !,J   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "I.)Q4GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"   (%@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>12</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20220428.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lly-20220428.htm">lly-20220428.htm</File>
    <File>lly-20220428.xsd</File>
    <File>lly-20220428_def.xml</File>
    <File>lly-20220428_lab.xml</File>
    <File>lly-20220428_pre.xml</File>
    <File>q122lillysalesandearningsp.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="52">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20220428.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 12,
   "dts": {
    "definitionLink": {
     "local": [
      "lly-20220428_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20220428.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20220428_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20220428_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20220428.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 38,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 10,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20220428",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220428.htm",
      "contextRef": "i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20220428.htm",
      "contextRef": "i6cbeeaa59436454d812d13c6f109f028_D20220428-20220428",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 11,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes due 2051",
        "label": "1.125% Notes due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2061",
        "label": "1.375% Notes due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625%\u00a0Notes due 2043",
        "label": "1.625%\u00a0Notes due 2043 [Member]",
        "terseLabel": "1.625%\u00a0Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A500NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2033",
        "label": ".500% Notes due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A500NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77% Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20220428",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000059478-22-000130-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-22-000130-xbrl.zip
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M-GRO'?2_+::]+.TYWS:+1:Y[PZ2?=W4!;0>I$(%PB!B9IG,R3"^E<<QJ_?P
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MTNZLK>YN;[0VUG:"E68]6/OOZK]7FNMKP>I6H[&QL[.QU?R)5<!WJL*>'G8
M.T6_]RZHUU9K >@+'EUAT!]"Y25LET-EL62?.S;*\]*;$C7"Y4/8C<+4F%Y/
M-0^E(<YKDD2/GBP5-2:O#Y[#;M,(4_2(L?&9BXK[T]JDCR!Z,.QGJ;TW/3X
M;1=L:>AMZ3-H@/"V,5EJ@(];VXW@"7<_3+>_C3?O_,S-#R?3S0_MO09OUM=X
M^[!-FBU#F_4#L05Y-%H'K-'Z,VMV&Q#VY;A!_4:&K]S^^U.V3[-O\>$ TCW
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M1UU Z.F3"XB9JZ/&/%6X;D!KF-:"8-L-1UDQ]*-Z"XAD<@DET$'P\9PI5OO
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M!E[1=_4^\N7]D2 /K_6/'=!E#KO?S%O[TZMGVT_L/X(O]:MG_P902P,$%
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M^.+DCLE^0&S/+NK3]1P-A!_W'FB)<7UZ_6+]1ONG_1' UR_^!U!+ P04
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MZIWSP/S ]?S53>_?+]P_$%?XHHU _ RFBD5^X9X?7/\>4@_>#G\YU#$YM4&
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M% 6.ZZ&T&5*0C8(*TN'=5CR\:\CACNM<_WI[^TD.US+Z-9H&)T@&X<LI2"_
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M+DW6D<:S:?">A?S#U0L6>8Q#? AZ5_INT12 GID[0YM/*;?=?" V3)T>*=X
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M\5A N4V&X1SH#"8,@&(<7XN/"XD;!C["()@PN7"Q];;1T]ID6K3WWHO\=3^
M$IZR_'7C"T)G1!^ -E V<("=&>!T(]<#)#F$?3,GU!DS L2#6T(( +PH@>T
MPN'[  B^D0\!;0?;Y+0,L=1LN3KL$$? 8A+V@!KA68N,P"[+)WH@D8 \%XV+
M8ZI)28P[*75EV$&/V*'5!1&<TAJ@$S0 ;#!#81-8= [16S YS""IQL=?F1_
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M1 9YSCQDP2/N_;G1U_IQU2IYE&Q@]M8P3F'_@H!XCOE/\: D]RES5&R)$U@
M=5XU]OC-@.&I.$$65:R 8KK-9@,@ <:$+Q- LE74XYP:D84U=D'D.H(2\(:$
MS/T1]S1RLM'%>PKRT5TG30[RL\5( H\Y8YE^+S-9P%$8XOT+YD=GY\L+P80!
MZA!W)H_!72QV"N_RL4!7%B2=M;MT\.H'Z!2LG.J0?X3VG+3T1L1CPQ#V*[)L
M0B?.27B<B-+S8I71NP5W 5+9-^:9W&>6K)",I$!]WP4>0"K.[#O#B>(&2WSZ
M7U7B_C6;:P..G"D((3>!@LYFGOM-5(L"4/:Z+PIS)GK]%\6)$N)F$(89!#W
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MDZQYX4'P%Z>*Q6 WQ?U281?9[A DW]^IA\R1B& 7M()H7L#=@)D3!]8VGC=
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M+3(P,C(P-#(X+FAT;5!+ 0(4 Q0    ( *DXG%1EMT^NOP,   T2   0
M          "  ?$?  !L;'DM,C R,C T,C@N>'-D4$L! A0#%     @ J3B<
M5,2G 0\S"@  0DT  !0              ( !WB,  &QL>2TR,#(R,#0R.%]D
M968N>&UL4$L! A0#%     @ J3B<5,XMJWWY$   5:4  !0
M ( !0RX  &QL>2TR,#(R,#0R.%]L86(N>&UL4$L! A0#%     @ J3B<5.W(
M+9[2"0  TE$  !0              ( !;C\  &QL>2TR,#(R,#0R.%]P<F4N
M>&UL4$L! A0#%     @ J3B<5-%^NP$K40  G6 $ !X              ( !
M<DD  '$Q,C)L:6QL>7-A;&5S86YD96%R;FEN9W-P+FAT;5!+!08     !@ &
+ (X!  #9F@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
